ADC Therapeutics SA (ADCT) - Total Liabilities
Based on the latest financial reports, ADC Therapeutics SA (ADCT) has total liabilities worth $507.87 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore ADCT long-term asset investment ratio to see how much of total assets are deployed in long-term investments.
ADC Therapeutics SA - Total Liabilities Trend (2016–2025)
This chart illustrates how ADC Therapeutics SA's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see ADC Therapeutics SA assets under control.
ADC Therapeutics SA Competitors by Total Liabilities
The table below lists competitors of ADC Therapeutics SA ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Bulten AB
ST:BULTEN
|
Sweden | Skr2.68 Billion |
|
Bny Mellon Municipal Income Inc
NYSE MKT:DMF
|
USA | $81.91 Million |
|
SRV YHTIOET OYJ
F:B7J1
|
Germany | €395.40 Million |
|
Group Eleven Resources Corp
V:ZNG
|
Canada | CA$940.88K |
|
IZMO Limited
NSE:IZMO
|
India | Rs848.53 Million |
|
Limes Schlosskliniken AG
XETRA:LIK
|
Germany | €20.16 Million |
|
Emmerson Resources Ltd
AU:ERM
|
Australia | AU$591.50K |
|
Hyloris Developmentsen Sa
BR:HYL
|
Belgium | €8.16 Million |
Liability Composition Analysis (2016–2025)
This chart breaks down ADC Therapeutics SA's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See ADCT equity to assets ratio to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.09 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -2.35 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 1.74 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how ADC Therapeutics SA's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for ADC Therapeutics SA (2016–2025)
The table below shows the annual total liabilities of ADC Therapeutics SA from 2016 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $508.98 Million | -2.98% |
| 2024-12-31 | $524.62 Million | +4.29% |
| 2023-12-31 | $503.03 Million | +22.27% |
| 2022-12-31 | $411.41 Million | -8.96% |
| 2021-12-31 | $451.88 Million | +153.60% |
| 2020-12-31 | $178.19 Million | +571.74% |
| 2019-12-31 | $26.53 Million | +9.09% |
| 2018-12-31 | $24.32 Million | +6.72% |
| 2017-12-31 | $22.78 Million | +60.64% |
| 2016-12-31 | $14.18 Million | -- |
About ADC Therapeutics SA
ADC Therapeutics SA provides antibody drug conjugate (ADC) technology platform in Switzerland and the United States. Its flagship product includes ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S. Food and Drug Administration, conditional approval from the European Commission, and conditional approval from the China National Medical Products Administration for the treatme… Read more